Iron sucrose and ferric carboxymaltose: No correlation between physicochemical stability and biological activity

BioMetals

Volumn 28, Issue 1, 2015, Pages 35-50

  Praschberger, Monika ^a   Haider, Kathrin ^a   Cornelius, Carolin ^a   Schitegg, Markus ^a   Sturm, Brigitte ^a   Goldenberg, Hans ^a   Scheiber Mojdehkar, Barbara ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ascorbic acid; Ferric carboxymaltose; Intravenous iron; Iron sucrose; Liver iron overload; Macrophages

Indexed keywords

APOTRANSFERRIN; ASCORBIC ACID; FERRIC CARBOXYMALTOSE; FERRITIN; IRON; IRON SACCHARATE; TRANSFERRIN; FERRIC ION; FERRIC OXIDE, SACCHARATED; MALTOSE; SACCHARIC ACID;

ARTICLE; BIOLOGICAL ACTIVITY; CYTOTOXICITY; HEMODIALYSIS; HEPG2 CELL LINE; HUMAN; IN VITRO STUDY; IRON STORAGE; LIVER PARENCHYMA; MACROPHAGE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; TRANSFERRIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; CELL LINE; DRUG EFFECTS; LIVER; METABOLISM;

ASCORBIC ACID; CELL LINE; FERRIC COMPOUNDS; FERRITINS; GLUCARIC ACID; HEP G2 CELLS; HUMANS; IRON; LIVER; MACROPHAGES; MALTOSE;

EID: 84922089300     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-014-9801-0     Document Type: Article

References (60)

1. Abelson J, Simon M, Deutscher M (1990) Methods in Enzymology: Guide to protein purification. Academic Press, Inc., San Diego
2. Attallah N, Osman-Malik Y, Frinak S, Besarab A (2006) Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47:644-654. doi:10.1053/j.ajkd.2005.12.025
3. Auerbach M, Goodnough LT, Picard D, Maniatis A (2008) The role of intravenous iron in anemia management and transfusion avoidance. Transfusion (Paris) 48:988-1000. doi:10.1111/j.1537-2995.2007.01633.x
4. Bailie GR, Mason NA, Valaoras TG (2010) Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. Int Symp Home Hemodial 14:47-54. doi:10.1111/j.1542-4758.2009.00409.x
5. Baldwin DA (1980) The kinetics of iron release from human transferrin by EDTA. Effect of salts and detergents. Biochim Biophys Acta 623:183-198
6. Breuer W, Cabantchik ZI (2001) A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299:194-202. doi:10.1006/abio.2001.5378
7. Breuer W, Epsztejn S, Cabantchik ZI (1995) Iron acquired from Transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem 270:24209-24215. doi:10.1074/jbc.270.41.24209
8. Breuer W, Greenberg E, Cabantchik ZI (1997) Newly delivered transferrin iron and oxidative cell injury. FEBS Lett 403:213-219
9. Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F (2004a) Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 19:1564-1570. doi:10.1093/ndt/gfh136
10. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A (2004b) Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65:1091-1098. doi:10.1111/j.1523-1755.2004.00480.x
11. Crichton RR, Danielson BG, Geisser P (2006) Iron therapy with special emphasis on intravenous administration. UNIMED, Bremen
12. Danielson BG (2004) Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(Suppl 2):S93-S98. doi:10.1097/01.ASN.0000143814.49713.C5
13. Danielson BG, Salmonson T, Derendorf H, Geisser P (1996) Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 46:615-621
14. Davy P, Bingham D, Walters G, Whicher JT (1982) Estimation of the saturation of serum transferrin by an electrophoretic technique. Ann Clin Biochem 19:57-59. doi:10.1177/000456328201900112
15. Einerson B, Nathorn C, Kitiyakara C, Sirada M, Thamlikitkul V (2011) The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis. J Med Assoc Thail Chotmaihet Thangphaet 94(Suppl 1):S134-S146
16. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI (2003) Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102:2670-2677. doi:10.1182/blood-2003-03-0807
17. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15:1623-1632
18. ferinject-smpc-2012.pdf [WWW Document], n.d. URL http://server-p007.hostpoint.ch/%7Eferinjec/ferinject.com/wpcontent/uploads/2011/12/ferinject-smpc-2012.pdf (accessed 26 Aug 2013)
19. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK (2011) Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6:77-83. doi:10.2215/CJN.04190510
20. Fish WW (1988) Rapid colorimetric micromethod for the quantitation of complexed iron in biological samples. Methods Enzymol 158:357-364
21. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E (2014) Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant doi:10.1093/ndt/gfu104
22. Geisser P, Baer M, Schaub E (1992) Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42:1439-1452
23. Ghoti H, Rachmilewitz EA, Simon-Lopez R, Gaber R, Katzir Z, Konen E, Kushnir T, Girelli D, Campostrini N, Fibach E, Goitein O (2012) Evidence for tissue iron overload in longterm hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 89:87-93. doi:10.1111/j.1600-0609.2012.01783.x
24. Halliwell B, Gutteridge JM (1990) Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 186:1-85
25. Halliwell B, Gutteridge JM (1999) Free radicals in biology and medicine, 3rd edn. Oxford Science Publications, New York
26. Hemmaplardh D, Morgan EH (1974) The mechanism of iron exchange between synthetic iron chelators and rabbit reticulocytes. Biochim Biophys Acta 373:84-99
27. Hoen B, Paul-Dauphin A, Hestin D, Kessler M (1998) EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9:869-876
28. Jahn MR, Andreasen HB, Fütterer S, Nawroth T, Schünemann V, Kolb U, Hofmeister W, Muñoz M, Bock K, Meldal M, Langguth P (2011) A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 78:480-491. doi:10.1016/j.ejpb.2011.03.016
29. Jalalzadeh M, Shekari E, Mirzamohammadi F, Ghadiani MH (2012) Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients. Indian J Nephrol 22:168-173. doi:10.4103/0971-4065.86407
30. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG(2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16:3070-3080. doi:10.1681/ASN.2005040423
31. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C (2008) A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 103:1182-1192. doi:10.1111/j.1572-0241.2007.01744.x
32. Kuo K-L, Hung S-C, Wei Y-H, Tarng D-C (2008) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 19:1817-1826. doi:10.1681/ASN.2007101084
33. Lim CS, Vaziri ND (2004) The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 65:1802-1809. doi:10.1111/j.1523-1755.2004.00580.x
34. Lipiński P, Drapier J-C, Oliveira L, Retmańska H, Sochanowicz B, Kruszewski M (2000) Intracellular iron status as a hallmark of mammalian cell susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines differentially sensitive to H2O2. Blood 95:2960-2966
35. Makey DG, Seal US (1976) The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta 453:250-256
36. McCord JM (1998) Iron, free radicals, and oxidative injury. Semin Hematol 35:5-12
37. Muñoz M, Breymann C, García-Erce JA, Gómez-Ramírez S, Comin J, Bisbe E (2008) Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 94:172-183. doi:10.1111/j.1423-0410.2007.01014.x
38. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15:1827-1834
39. Picard V, Renaudie F, Porcher C, Hentze MW, Grandchamp B, Beaumont C (1996) Overexpression of the ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution. Blood 87:2057-2064
40. Pierre JL, Fontecave M, Crichton RR (2002) Chemistry for an essential biological process: the reduction of ferric iron. Biometals 15:341-346. doi:10.1023/A:1020259021641
41. Pollack S, Vanderhoff G, Lasky F (1977) Iron removal from transferrin. An experimental study. Biochim Biophys Acta 497:481-487
42. Praschberger M, Cornelius C, Schitegg M, Goldenberg H, Scheiber-Mojdehkar B, Sturm B (2013) Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD. Pharm Dev Technol doi:10.3109/10837450.2013.852575
43. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y (2012) Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 125(991-999):e1. doi:10.1016/j.amjmed.2012.01.015
44. Rothman RJ, Serroni A, Farber JL (1992) Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 42:703-710
45. Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2:406-414. doi:10.1038/nchembio807
46. Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Hörl WH, Födinger M, Sunder-Plassmann G, Vychytil A (2005) Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int 68:2814-2822. doi:10.1111/j.1523-1755.2005.00754.x
47. Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H (2003) Influence of parenteral iron preparations on nontransferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem Pharmacol 65:1973-1978. doi:10.1016/S0006-2952(03)00181-3
48. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M (2002) Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif Organs 26:366-370
49. Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, Mayer G, Weiss G (2011) Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 26:977-987. doi:10.1093/ndt/gfq483
50. Stäubli A, Boelsterli UA (1998) The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am J Physiol-Gastrointest Liver Physiol 274:G1031-G1037
51. Sturm B, Goldenberg H, Scheiber-Mojdehkar B (2003) Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem 270:3731-3738. doi:10.1046/j.1432-1033.2003.03759.x
52. Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B (2005) Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int 67:1161-1170. doi:10.1111/j.1523-1755.2005.00183.x
53. Sturm B, Steinkellner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B (2010) In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress. Arzneimittelforschung 60:459-465. doi:10.1055/s-0031-1296312
54. Tarng D-C (2007) Novel aspects of vitamin C in epoetin response. J Chin Med Assoc 70:357-360. doi:10.1016/S1726-4901(08)70020-0
55. Toblli JE, Cao G, Oliveri L, Angerosa M (2012) Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflamm Allergy Drug Targets 11:66-78
56. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, Tada K (1982) Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42:1530-1536
57. Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A (2007) Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 110:267-278. doi:10.1097/01.AOG.0000275286.03283.18
58. Venofer-Iron sucrose injection, USP [WWW Document], n.d. URL http://www.venofer.com/HCP/Index.aspx (accessed 26 Aug 2013)
59. Wang S, Geraci G, Kuhlmann MK, Levin NW, Handelman GJ (2008) Chemical reactions of vitamin C with intravenousiron formulations. Nephrol Dial Transplant 23:120-125. doi:10.1093/ndt/gfm557
60. Young SP, Roberts S, Bomford A (1985) Intracellular processing of transferrin and iron by isolated rat hepatocytes. Biochem J 232:819-823